Introduction: Bladder cancer is a urological malignancy with high incidence and recurrence rates. Transurethral resection of the bladder (TURB) is the main therapeutic procedure for non-muscle invasive bladder tumors, characterized by the absence of invasion into the bladder muscle layer. In addition to its therapeutic role, TURB is essential for the initial staging of the disease. Despite being widelyperformed, its effectiveness in terms of population clinical outcomes, such as mortality and hospitalizations, still lacks systematic evaluation in the Brazilian context. Objectives: To evaluate the effectiveness of transurethral resection in bladder cancer patients by analyzing the correlation between the number of endoscopic resections of bladder tumors, hospitalizations, and deaths from bladder neoplasms in Brazil between 2020 and 2023. Methods: This is an ecological study based on secondary data extracted from the public database TABNET/DATASUS, covering the period from 2020 to 2023. Three annual variables were analyzed: the number of endoscopic resections of bladder tumors, the number of hospitalizations for malignant bladder neoplasms, and the number of deaths due to malignant bladder neoplasms. The association between these variables was assessed using Pearson correlation (linear association) and Spearman correlation (monotonic association). Results: A strong positive correlation was observed between the evaluated indicators. The Pearson correlation between resections and deaths was 0.9989, between resections and hospitalizations was 0.9987, and between hospitalizations and deaths was 0.9999. The Spearman coefficients were 1.0 in all comparisons. These findings suggest a parallel behavior between the three indicators, with a simultaneous increase from 2020 to 2023. The high correlation between endoscopic resections, hospitalizations, and deaths from bladder câncer suggests that TURB, although widely performed, has been applied in contexts of high disease burden, often associated with late-stage diagnoses, which limits its isolated impact on mortality reduction. Conclusion: Therefore, the data emphasize the need for complementary strategies such as screening programs, early diagnosis, and rigorous follow-up to enhance the benefits of TURB in the management of bladder cancer.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
